中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Menu
Volume 35 Issue 1
Jan.  2019
Turn off MathJax
Article Contents
Abstract
References
Article Navigation >  Journal of Clinical Hepatology  > 2019  >  35(1): 201-204

Prognostic evaluation of transjugular intrahepatic portosystemic shunt in treatment of cirrhotic portal hypertension

DOI: 10.3969/j.issn.1001-5256.2019.01.044

  • Department of Gastroenterology, The Second Affiliated Hospital of Kunming Medical University, Kunming 650101, China

  • Published Date: 2019-01-20
    Abstract

  • Transjugular intrahepatic portosystemic shunt (TIPS) is an important method for the treatment of cirrhotic portal hypertension;however, its clinical application is limited by postoperative complications such as liver failure and hepatic encephalopathy.This article summarizes and analyzes the research advances in the clinical value of serological markers, clinical indices, and scoring systems in prognostic evaluation of TIPS.Indices can be selected or comprehensive evaluation can be performed based on clinical situations, in order to improve patients’postoperative survival rate.

     

    • FullText(HTML)
    • References(32)
  • [1]ROSSLE M, RICHTER GM, NOLDGE G, et al.New non-operative treatment for variceal hemorrhage[J].Lancet, 1989, 2 (8655) :153.
    [2]DING ZF, YIN SW.Application of Viatorr covered stent in transjugular intrahepatic portosystemic shunt[J].J Clin Hepatol, 2018, 34 (5) :1107-1110. (in Chinese) 丁智锋, 殷世武.Viatorr覆膜支架在经颈静脉肝内门体分流术中的应用现状[J].临床肝胆病杂志, 2018, 34 (5) :1107-1110.
    [3]CHEN SL, HU P, LIN ZP, et al.Relevant factors analysis on significant increase of total bilirubin in short term after TIPS and its influence on survival prognosis[J].Chin J Inter Rad:Electronic Edition, 2018, 6 (1) :40-45. (in Chinese) 陈斯良, 胡朋, 林志鹏, 等.TIPS术后短期总胆红素显著升高的相关因素分析及其对生存预后的影响[J].中华介入放射学电子杂志, 2018, 6 (1) :40-45.
    [4]YOON CJ, CHUNG JW, PARK JH.Transjugular intrahepatic portosystemic shunt for acute variceal bleeding in patients with viral liver cirrhosis:Predictors of early mortality[J].AJR Am JRoentgenol, 2005, 185 (4) :885-889.
    [5]BUREAU C, MTIVIER S, D'AMICO M, et al.Serum bilirubin and platelet count:A simple predictive model for survival in patients with refractory ascites treated by TIPS[J].J Hepatol, 2011, 54 (5) :901-907.
    [6]QI X, HE C, GUO W, et al.Transjugular intrahepatic portosystemic shunt for portal vein thrombosis with variceal bleeding in liver cirrhosis:Outcomes and predictors in a prospective cohort study[J].Liver Int, 2016, 36 (5) :667-676.
    [7]WANG LZ, LI X, SONG J, et al.Predictive factors for improved ascites after transjugular intrahepatic portosystemic shunt in patients with refractory ascites[J].J Pract Radiol, 2015, 31 (5) :777-781. (in Chinese) 王黎洲, 李兴, 宋杰, 等.肝硬化合并顽固性腹水患者TIPS术后腹水改善的相关因素分析[J].实用放射学杂志, 2015, 31 (5) :777-781.
    [8]JU W, ZHANG BJ, HAN GH.Long-term therapeutic effect of transjugular intrahepatic portosystemic shunt in patients with intractable cirrhotic ascites and prognostic factors[J].J Clin Hepatol, 2016, 32 (8) :1529-1533. (in Chinese) 巨伟, 张博静, 韩国宏.经颈静脉肝内门体分流术治疗肝硬化顽固性腹水的长期效果及预后因素分析[J].临床肝胆病杂志, 2016, 32 (8) :1529-1533.
    [9]NEGISHI M, WONGPALEE SP, SARKAR S, et al.A new lncRNA, APTR, associates with and represses the CDKN1A/p21 promoter by recruiting polycomb proteins[J].PLo S One, 2014, 9 (4) :e95216.
    [10]YU F, ZHENG J, MAO Y, et al.Long non-coding RNA APTRpromotes the activation of hepatic stellate cells and the progression of liver fibrosis[J].Biochem Biophys Res Commun, 2015, 463 (4) :679-685.
    [11]YU S, QI Y, JIANG J, et al.APTR is a prognostic marker in cirrhotic patients with portal hypertension during TIPS procedure[J].Gene, 2018, 645:30-33.
    [12]TACKE F, ZIMMERMANN HW, BERRES ML, et al.Serum chemokine receptor CXCR3 ligands are associated with progression, organ dysfunction and complications of chronic liver diseases[J].Liver Int, 2011, 31 (6) :840-849.
    [13]BERRES ML, ASMACHER S, LEHMANN J, et al.CXCL9 is a prognostic marker in patients with liver cirrhosis receiving transjugular intrahepatic portosystemic shunt[J].J Hepatol, 2015, 62 (2) :332-339.
    [14]BERRES ML, LEHMANN J, JANSEN C, et al.Chemokine (C-X-C motif) ligand 11 levels predict survival in cirrhotic patients with transjugular intrahepatic portosystemic shunt[J].Liver Int, 2016, 36 (3) :386-394.
    [15]JANSEN C, EISCHEID H, GOERTZEN J, et al.The role of miRNA-34a as a prognostic biomarker for cirrhotic patients with portal hypertension receiving TIPS[J].PLo S One, 2014, 9 (7) :e103779
    [16]PUGH RN, MURRAY-LYON IM, DAWSON JL, et al.Transection of the oesophagus for bleeding oesophageal varices[J].Br J Surg, 1973, 60 (8) :646-649.
    [17]CHEN H, BAI M, QI X, et al.Child-Na score:A predictive model for survival in cirrhotic patients with symptomatic portal hypertension treated with TIPS[J].PLo S One, 2013, 8 (11) :e79637
    [18]KAMATH PS, WIESNER RH, MALINCHOC M, et al.A model to predict survival in patients with end-stage liver disease[J].Hepatology, 2001, 33 (2) :464-470.
    [19]WANG HQ, LIN Y, YAN Y.Clinical study on the significcance of hyponatremia in patients with cirrhotic ascites[J].J Clin Exp Med, 2017, 16 (22) :2275-2278. (in Chinese) 王慧卿, 林叶, 严艳.肝硬化腹水合并低钠血症的临床研究[J].临床和实验医学杂志, 2017, 16 (22) :2275-2278.
    [20]GABA RC, COUTURE PM, BUI JT, et al.Prognostic capability of different liver disease scoring systems for prediction of early mortality after transjugular intrahepatic portosystemic shunt creation[J].J Vasc Interv Radiol, 2013, 24 (3) :411-420.
    [21]ZHOU C, HOU C, CHENG D, et al.Predictive accuracy comparison of MELD and Child-Turcotte-Pugh scores for survival in patients underwent TIPS placement:A systematic metaanalytic review[J].Int J Clin Exp Med, 2015, 8 (8) :13464-13472.
    [22]PENG Y, QI X, GUO X.Child-Pugh versus MELD score for the assessment of prognosis in liver cirrhosis:A systematic review and meta-analysis of observational studies[J].Medicine (Baltimore) , 2016, 95 (8) :e2877.
    [23]PROCOPE B, TANTAU M, BUREAU C.Are there any alternative methods to hepatic venous pressure gradient in portal hypertension assessment?[J].J Gastrointestin Liver Dis, 2013, 22 (1) :73-78.
    [24]XU ZG, ZHAO YB, ZHENG YY, et al.Association between portal vein pressure drop gradient after transjugular intrahepatic portosystemic shunt and clinical prognosis[J].J Clin Hepatol, 2016, 32 (12) :2326-2330. (in Chinese) 徐征国, 赵泳冰, 郑媛钰, 等.肝硬化患者经颈静脉肝内门体分流术后门静脉压力下降梯度与预后的关系[J].临床肝胆病杂志, 2016, 32 (12) :2326-2330.
    [25]ASCHA M, ABUQAYYAS S, HANOUNEH I, et al.Predictors of mortality after transjugular portosystemic shunt[J].World JHepatol, 2016, 8 (11) :520-529.
    [26]QI X, GUO W, HE C, et al.Transjugular intrahepatic portosystemic shunt for Budd-Chiari syndrome:Techniques, indications and results on 51 Chinese patients from a single centre[J].Liver Int, 2014, 34 (8) :1164-1175.
    [27]DELTENRE P, TRPO E, RUDLER M, et al.Early transjugular intrahepatic portosystemic shunt in cirrhotic patients with acute variceal bleeding:A systematic review and meta-analysis of controlled trials[J].Eur J Gastroenterol Hepatol, 2015, 27 (9) :e1-e9.
    [28]RUDLER M, CLUZEL P, CORVEC TL, et al.Early-TIPSSplacement prevents rebleeding in high-risk patients with variceal bleeding, without improving survival[J].Aliment Pharmacol Ther, 2014, 40 (9) :1074-1080.
    [29]PARVINIAN A, SHAH KD, COUTURE PM, et al.Older patient age may predict early mortality after transjugular intrahepatic portosystemic shunt creation in individuals at intermediate risk[J].J Vasc Interv Radiol, 2013, 24 (7) :941-946.
    [30]LI Y, WANG F, CHEN X, et al.Short outcome comparison of elderly patients versus nonelderly patients treated with transjugular intrahepatic portosystemic stent shunt:A propensity score matched cohort study[J].Medicine (Baltimore) , 2017, 96 (29) :e7551.
    [31]SURAWEERA D, JIMENEZ M, VIRAMONTES M, et al.Agerelated morbidity and mortality after transjugular intrahepatic portosystemic shunts[J].J Clin Gastroenterol, 2017, 51 (4) :360-363.
    [32]NARDELLI S, LATTANZI B, TORRISI S, et al.Sarcopenia is risk factor for development of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt placement[J].Clin Gastroenterol Hepatol, 2017, 15 (6) :934-936.
    • Relative Articles

  • Relative Articles

    [1]Kexin QIAO, Guiqin ZHOU, Yaxing LIU, Ying FENG, Yao LIU, Bin LI, Xianbo WANG. Clinical features of primary biliary cholangitis patients with negative or positive anti-mitochondrial antibody： A comparative study[J]. Journal of Clinical Hepatology, 2024, 40(9): 1778-1784. doi: 10.12449/JCH240910
    [2]Cui NaNa, Wang QiXia. Diagnosis and differential diagnosis of autoimmune hepatitis[J]. Journal of Clinical Hepatology, 2020, 36(4): 724-727. doi: 10.3969/j.issn.1001-5256.2020.04.002
    [3]Zhang LiXia, Huang Xu, Sun XiaoJie, Zhang Ying, Lu ShaSha, Shi XiaoDong, Ji HuiFan, Guo XiaoLin. A case of antimitochondrial antibody-negative primary biliary cholangitis[J]. Journal of Clinical Hepatology, 2019, 35(1): 179-181. doi: 10.3969/j.issn.1001-5256.2019.01.038
    [4]Han Ying, Chen Jie, Dan Jing, Liu YanMin, Zhang XiaoDan, Ren MeiXin, Du XiaoFei, Bian XinQu, Liu Dan, Huang YunLi, Huang ChunYang, Liao HuiYu. Value of fumarate hydratase antibody in differential diagnosis of autoimmune hepatitis and drug-induced liver injury[J]. Journal of Clinical Hepatology, 2019, 35(6): 1326-1329. doi: 10.3969/j.issn.1001-5256.2019.06.029
    [5]Liu HongLi, Yang YongFeng. Clinical and pathological features of primary biliary cholangitis with negative anti-mitochondrial antibody[J]. Journal of Clinical Hepatology, 2019, 35(3): 677-680. doi: 10.3969/j.issn.1001-5256.2019.03.051
    [6]Bian ZhaoLian, Shao JianGuo, Ma Xiong. Differential diagnosis of drug-induced liver injury and autoimmune hepatitis and related therapeutic strategies[J]. Journal of Clinical Hepatology, 2018, 34(6): 1156-1159. doi: 10.3969/j.issn.1001-5256.2018.06.003
    [7]Luo WenPing, Ma Hong, Zhao XinYan. Pathological features of hepatic vascular diseases and key points in differential diagnosis[J]. Journal of Clinical Hepatology, 2018, 34(11): 2289-2294. doi: 10.3969/j.issn.1001-5256.2018.11.005
    [8]Jiang LiLin, Shen JianBo, Tang Hong, Lu ZhongHua. Pathological differential diagnosis of inflammatory liver injury[J]. Journal of Clinical Hepatology, 2018, 34(11): 2278-2282. doi: 10.3969/j.issn.1001-5256.2018.11.003
    [9]Du XiaoFeng, Ma ZhouPeng, Lin GuanSheng, He Hui, Tang YaRong, Wu JianMing. CT diagnosis and differentiation of nodular/mass-type hepatic lymphoma[J]. Journal of Clinical Hepatology, 2017, 33(8): 1492-1496. doi: 10.3969/j.issn.1001-5256.2017.08.016
    [10]Li Jing, Tang ShaoShan, Yu HongWei. Value of contrast-enhanced ultrasound in differential diagnosis of single metastatic liver cancer and solitary necrotic nodule of the liver[J]. Journal of Clinical Hepatology, 2016, 32(7): 1338-1341. doi: 10.3969/j.issn.1001-5256.2016.07.025
    [11]Wang Sui, Wang JiangBin. The diagnosis and treatment of primary biliary cirrhosis[J]. Journal of Clinical Hepatology, 2015, 31(10): 1605-1607. doi: 10.3969/j.issn.1001-5256.2015.10.010
    [12]Chinese Society of Hepatology, Chinese Medical Association; Chinese Society of Gastroenterology, Chinese Medical Association; Chinese Society of Infectious Diseases, Chinese Medical Association. Consensus on the diagnosis and management of primary biliary cirrhosis (cholangitis)(2015)[J]. Journal of Clinical Hepatology, 2015, 31(12): 1980-1988. doi: 10.3969/j.issn.1001-5256.2015.12.004
    [13]Zhang AnYuan, Chen Hao, Zhao Peng, Gong JianPing. Differential diagnosis of autoimmune pancreatitis from pancreatic cancer[J]. Journal of Clinical Hepatology, 2015, 31(5): 783-786. doi: 10.3969/j.issn.1001-5256.2015.05.038
    [14]Guo Jing, Xu LingFen, Sun Mei. Differential diagnosis of biliary atresia and intrahepatic cholestasis in children[J]. Journal of Clinical Hepatology, 2015, 31(8): 1252-1256. doi: 10.3969/j.issn.1001-5256.2015.08.017
    [15]Cao ZhangChun. Significance of combined analysis of autoantibodies in diagnosis of primary biliary cirrhosis[J]. Journal of Clinical Hepatology, 2015, 31(2): 178-180. doi: 10.3969/j.issn.1001-5256.2015.02.008
    [16]Li YinPing, Niu JunQi. Significance of serum anti-gp210 antibody detection in diagnosis of primary biliary cirrhosis[J]. Journal of Clinical Hepatology, 2014, 30(5): 466-468. doi: 10.3969/j.issn.1001-5256.2014.05.023
    [17]Zhao DanTong, Liao HuiYu, Liu YanMin, Huang ChunYang, Zhang HaiPing, Sun LiMei, Ma YinXue, Zhao Yan, Yan HuiPing. ROC analysis of prognostic factors in Chinese patients with primary biliary cirrhosis[J]. Journal of Clinical Hepatology, 2014, 30(1): 62-66. doi: 10.3969/j.issn.1001-5256.2014.01.017
    [18]Li Bing, Shao Qing, Niu XiaoXia, Zhang Jian, Chen GuoFeng. Clinical features and diagnosis of autoimmune hepatitis-primary biliary cirrhosis overlap syndrome[J]. Journal of Clinical Hepatology, 2014, 30(5): 413-416. doi: 10.3969/j.issn.1001-5256.2014.05.007
    [19]Zhang Li, Bai ShiShan. Research progress on laboratory diagnosis of primary biliary cirrhosis[J]. Journal of Clinical Hepatology, 2011, 27(10): 1109-1111+1120.
    • Supplements(0)
    • Cited By
  • 加载中
    Created with Highcharts 5.0.7Chart context menuAccess Class DistributionFULLTEXT: 15.4 %FULLTEXT: 15.4 %META: 75.2 %META: 75.2 %PDF: 9.3 %PDF: 9.3 %FULLTEXTMETAPDF
    Created with Highcharts 5.0.7Chart context menuAccess Area Distribution其他: 8.7 %其他: 8.7 %其他: 1.8 %其他: 1.8 %Central District: 0.1 %Central District: 0.1 %China: 0.9 %China: 0.9 %India: 0.9 %India: 0.9 %Jamaica Plain: 0.1 %Jamaica Plain: 0.1 %Rochester: 0.1 %Rochester: 0.1 %Russian Federation: 0.1 %Russian Federation: 0.1 %United States: 0.2 %United States: 0.2 %[]: 0.6 %[]: 0.6 %上海: 3.2 %上海: 3.2 %东莞: 0.3 %东莞: 0.3 %临汾: 0.1 %临汾: 0.1 %丽水: 0.1 %丽水: 0.1 %佛山: 0.2 %佛山: 0.2 %信阳: 0.2 %信阳: 0.2 %北京: 3.3 %北京: 3.3 %南京: 0.9 %南京: 0.9 %南宁: 0.7 %南宁: 0.7 %南平: 0.1 %南平: 0.1 %南阳: 0.1 %南阳: 0.1 %卡纳塔克: 0.2 %卡纳塔克: 0.2 %吉打州: 0.3 %吉打州: 0.3 %吉林: 0.4 %吉林: 0.4 %哥伦布: 0.1 %哥伦布: 0.1 %大连: 0.6 %大连: 0.6 %天津: 0.3 %天津: 0.3 %太原: 0.1 %太原: 0.1 %宝鸡: 0.2 %宝鸡: 0.2 %岳阳: 0.1 %岳阳: 0.1 %常德: 0.1 %常德: 0.1 %广州: 2.6 %广州: 2.6 %张家口: 5.1 %张家口: 5.1 %徐州: 0.1 %徐州: 0.1 %成都: 1.1 %成都: 1.1 %拉贾斯坦邦: 0.1 %拉贾斯坦邦: 0.1 %新泽西州: 0.3 %新泽西州: 0.3 %昆明: 0.7 %昆明: 0.7 %晋城: 0.1 %晋城: 0.1 %杭州: 1.0 %杭州: 1.0 %武汉: 1.2 %武汉: 1.2 %法兰克福: 0.2 %法兰克福: 0.2 %法拉盛: 0.2 %法拉盛: 0.2 %济南: 0.2 %济南: 0.2 %海得拉巴: 0.2 %海得拉巴: 0.2 %深圳: 0.4 %深圳: 0.4 %湘潭: 0.1 %湘潭: 0.1 %漯河: 0.1 %漯河: 0.1 %澳门: 0.3 %澳门: 0.3 %琼海: 0.2 %琼海: 0.2 %石家庄: 1.3 %石家庄: 1.3 %福州: 0.1 %福州: 0.1 %芒廷维尤: 35.6 %芒廷维尤: 35.6 %芝加哥: 0.1 %芝加哥: 0.1 %莫斯科: 2.2 %莫斯科: 2.2 %衢州: 0.1 %衢州: 0.1 %西孟加拉邦: 0.1 %西孟加拉邦: 0.1 %西宁: 14.7 %西宁: 14.7 %西安: 0.4 %西安: 0.4 %贵阳: 0.1 %贵阳: 0.1 %赤峰: 0.1 %赤峰: 0.1 %运城: 1.8 %运城: 1.8 %通辽: 0.2 %通辽: 0.2 %重庆: 0.1 %重庆: 0.1 %长春: 1.4 %长春: 1.4 %长沙: 0.9 %长沙: 0.9 %阿什本: 0.3 %阿什本: 0.3 %香港: 0.3 %香港: 0.3 %驻马店: 0.1 %驻马店: 0.1 %黄冈: 0.1 %黄冈: 0.1 %其他其他Central DistrictChinaIndiaJamaica PlainRochesterRussian FederationUnited States[]上海东莞临汾丽水佛山信阳北京南京南宁南平南阳卡纳塔克吉打州吉林哥伦布大连天津太原宝鸡岳阳常德广州张家口徐州成都拉贾斯坦邦新泽西州昆明晋城杭州武汉法兰克福法拉盛济南海得拉巴深圳湘潭漯河澳门琼海石家庄福州芒廷维尤芝加哥莫斯科衢州西孟加拉邦西宁西安贵阳赤峰运城通辽重庆长春长沙阿什本香港驻马店黄冈

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Get Citation
    PDF
    XML

    Article Metrics

    Article views (1734) PDF downloads(300) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[2462]YesterdayPV[4905]TodayIP[189]TodayPV[384]Online[25]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return